BACKGROUND: Matrix metalloproteinases (MMPs) play an important role in smooth muscle cell (SMC) migration and proliferation during vascular remodelling. To investigate the expression of MMP-12 by SMCs, we examined the protein secretion and mRNA expression of MMP-12 by cultured medial SMCs and intimal SMCs derived from human aortic atherosclerotic lesions. To further elucidate the molecular mechanism for MMP-12 expression in SMCs, we determined the sequence requirements for MMP-12 gene transcriptional activity. RESULTS: Cultured medial SMCs and intimal SMCs showed substantial MMP-12 expression at both the protein and mRNA levels. A series of 5'-deletion and site-directed mutants of the human MMP-12 promoter demonstrated that an AP-1 site spanning -81 to -75 bp was critical for the MMP-12 promoter activity in SMCs. An electrophoretic mobility shift assay confirmed the AP-1 binding activity in SMCs and showed that the protein bound to the AP-1 site consisted predominantly of c-Jun, JunD and Fra-1. Two structurally different inhibitors of phosphatidylinositol 3-kinase, wortmannin and LY294002, inhibited MMP-12 transcriptional activity and AP-1 binding. CONCLUSION: These results indicated the expression of MMP-12 in vascular SMCs and showed that the MMP-12 gene expression was dependent on the AP-1 binding activity. Phosphatidylinositol 3-kinase signalling may be involved in MMP-12 transcriptional activation through AP-1 binding activity.
BACKGROUND: Matrix metalloproteinases (MMPs) play an important role in smooth muscle cell (SMC) migration and proliferation during vascular remodelling. To investigate the expression of MMP-12 by SMCs, we examined the protein secretion and mRNA expression of MMP-12 by cultured medial SMCs and intimal SMCs derived from human aortic atherosclerotic lesions. To further elucidate the molecular mechanism for MMP-12 expression in SMCs, we determined the sequence requirements for MMP-12 gene transcriptional activity. RESULTS: Cultured medial SMCs and intimal SMCs showed substantial MMP-12 expression at both the protein and mRNA levels. A series of 5'-deletion and site-directed mutants of the humanMMP-12 promoter demonstrated that an AP-1 site spanning -81 to -75 bp was critical for the MMP-12 promoter activity in SMCs. An electrophoretic mobility shift assay confirmed the AP-1 binding activity in SMCs and showed that the protein bound to the AP-1 site consisted predominantly of c-Jun, JunD and Fra-1. Two structurally different inhibitors of phosphatidylinositol 3-kinase, wortmannin and LY294002, inhibited MMP-12 transcriptional activity and AP-1 binding. CONCLUSION: These results indicated the expression of MMP-12 in vascular SMCs and showed that the MMP-12 gene expression was dependent on the AP-1 binding activity. Phosphatidylinositol 3-kinase signalling may be involved in MMP-12 transcriptional activation through AP-1 binding activity.
Authors: Rugmani Padmanabhan Iyer; Nicolle L Patterson; Fouad A Zouein; Yonggang Ma; Vincent Dive; Lisandra E de Castro Brás; Merry L Lindsey Journal: Int J Cardiol Date: 2015-03-05 Impact factor: 4.164
Authors: Kristine Y DeLeon-Pennell; Cesar A Meschiari; Mira Jung; Merry L Lindsey Journal: Prog Mol Biol Transl Sci Date: 2017-03-18 Impact factor: 3.622
Authors: Xiucui Ma; Mindy Tittiger; Russell H Knutsen; Attila Kovacs; Laura Schaller; Robert P Mecham; Katherine P Ponder Journal: Mol Genet Metab Date: 2008-05-13 Impact factor: 4.797
Authors: Jason A Metcalf; Bruce Linders; Susan Wu; Paul Bigg; Patricia O'Donnell; Meg M Sleeper; Michael P Whyte; Mark Haskins; Katherine P Ponder Journal: Mol Genet Metab Date: 2009-12-11 Impact factor: 4.797